It is estimated there are 400 million people with presbyopia in China

LENZ Therapeutics reported its non-pilocarpine presbyopia drop, LNZ100 (1.75% aceclidine HCl), met its primary endpoint in a phase 3 Chinese study, with 74% of participants achieving three lines or greater improvement at three hours post treatment.

The results mirrored those of the company’s earlier Clarity trials in US subjects, with Chinese patients also maintaining their optimal distance visual acuity (ie. not losing five or more letters) while using the drops. Overall, 91% of Chinese participants indicated they noticed an improvement in their near vision, said the company.

The drop showed rapid onset and sustained effect, with 69% of participants achieving three lines or greater improvement at 30 minutes and 30% of participants at 10 hours, said the company. It was also well tolerated with no serious treatment-related adverse events observed in the trial.

The study further validates the company’s vision of targeting an “all eyes, all day” solution, said Eef Schimmelpennink, president and CEO of LENZ Therapeutics. “With these data, we believe LNZ100 has further enhanced its potential as a global therapy and is further on its path towards providing access to the estimated 400 million people with presbyopia in China.”